suPARnostic® is the only CE-IVD certified product range applied for clinical determination of soluble urokinase Plasminogen Activator Receptor (suPAR) in human EDTA and heparin-plasma.


suPARnostic® offers important clinical benefits:

  • Non-specific biomarker for risk-stratification across diseases
  • Faster patient prognosis and aid to prioritize patients
  • Low suPAR levels support the decision to discharge a patient

suPARnostic® is available in two different versions.

Quantitative Point of Care Quick Triage test

For Patient Triage in Acute Care.

See product

Quantitative ELISA Assay

For Clinical Routine Use.

See product